Human serum paraoxonase-1 (hPON1): in vitro inhibition effects of moxifloxacin hydrochloride, levofloxacin hemihidrate, cefepime hydrochloride, cefotaxime sodium and ceftizoxime sodium

References

• Kamruzzamana M, Alam AM, Lee SH, et al. Spectrofluorimetric study of the interaction between europium(III) and moxifloxacin in micellar solution and its analytical application. Spectrochim Acta A 2012;86:375–80
   Web of Science ®Google Scholar
• Cruz LA, Hall R. Enantiomeric purity assay of moxifloxacin hydrochloride by capillary electrophoresis. J Pharmaceut Biomed 2005;38:8–13
   PubMed Web of Science ®Google Scholar
• Ocana JA, Callejon M, Barragan FJ. Terbium-sensitized luminescence determination of levofloxacin in tablets and human urine and serum. Analyst 2000;125:1851–4
   PubMed Web of Science ®Google Scholar
• Lacy CF, Armstrong LL, Goldman MP, Lance L. Drug information handbook with international trade names index. 18th ed. Lexi-Comp; 2010.22:1134–47
   Google Scholar
• Cheathama SC, Sheab KM, Healyc DP, et al. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents 2011;37:46–50
   PubMed Web of Science ®Google Scholar
• Chena D, Wanga H, Zhangb Z, et al. Chemiluminescence determination of cefotaxime sodium with flow-injection analysis of cerium (IV)–rhodamine 6G system and its application to the binding study of cefotaxime sodium to protein with on-line microdialysis sampling. Spectrochim Acta A 2011;78:553–7
   Web of Science ®Google Scholar
• Bharath C, Prasad CS, Bharathi DV, et al. Structural identification and characterization of impurities in ceftizoxime sodium. J Pharm Biomed Anal 2007;43:733–40
   PubMed Web of Science ®Google Scholar
• Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Bio Med 1999;26:892–04
   PubMed Web of Science ®Google Scholar
• Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329–36
   PubMedGoogle Scholar
• Mackness MI, Mackness B, Arrol S, et al. Presence of paraoxonase in human interstitial fluid. FEBS Lett 1997;416:377–80
   PubMed Web of Science ®Google Scholar
• Aharoni A, Gaidukov L, Khersonsky O, et al. The evolvability of promiscuous protein functions. Nat Genet 2005;37:73–6
   PubMed Web of Science ®Google Scholar
• Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005;44:6371–82
   PubMed Web of Science ®Google Scholar
• Ates O, Azizi S, Alp HH, et al. Decreased serum paraoxonase 1 activity and increased homocysteine and malondialdehyde levels in age-related macular degeneration. Tohoku J Exp Med 2009;217:17–22
   PubMed Web of Science ®Google Scholar
• Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions. Circulation 2000;101:2510–7
   PubMed Web of Science ®Google Scholar
• Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidised low densitylipoprotein. J Clin Invest 1995;96:2882–91
   PubMed Web of Science ®Google Scholar
• Aviram M, Rosenblat M, Bisgair CL. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581–90
   PubMed Web of Science ®Google Scholar
• Ekmekci O, Donma O, Ekmekci H. Paraoxonase. Cerrahpaşa J Med 2004;35:78–82
   Google Scholar
• Abbott CA, Mackness MI, Kumar S, et al. Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscl Throm Vas Biol 1995;15:1812–18
   PubMed Web of Science ®Google Scholar
• Ayub A, Mackness MI, Arrol S, et al. Serum paraoxonase after myocardial infarction. Arterioscl Throm Vas Biol 1999;19:330–5
   PubMed Web of Science ®Google Scholar
• Baskol G, Karakucuk S, Oner AO, et al. Serum paraoxonase 1 activity and peroxidation levels in patients with age-related macular degeneration. Ophthalmologica 2006;220:12–16
   PubMed Web of Science ®Google Scholar
• Dantoine TF, Depord J, Charmes JP, et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998;9:2082–8
   PubMed Web of Science ®Google Scholar
• Mackness B, Mackness MI, Arrol S, et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity, concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998;139:341–9
   PubMed Web of Science ®Google Scholar
• Pla A, Rodrigo L, Hernandez AF, Gil Lopez FO. Effect of metal ions and calcium on purified PON1 and PON3 from rat liver. Chem-Biol Interact 2007;167:63–70
   PubMed Web of Science ®Google Scholar
• Sinan S, Kockar F, Arslan O. Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglikozide derived antibiotics. Biochimie 2006;88:565–74
   PubMed Web of Science ®Google Scholar
• Ekinci D, Beydemir S. Effect of some analgesics on paraoxonase-1 purified from human serum. J Enzyme Inhib Med Chem 2009;24:1034–9
   PubMed Web of Science ®Google Scholar
• Isgor MM, Beydemir S. Some cardiovascular therapeutics inhibit paraoxonase 1 (PON1) from human serum. Eur J Pharmacol 2010;645:135–42
   PubMed Web of Science ®Google Scholar
• Beydemir S, Ciftci M, Kufrevioglu OI. Purification and characterization of glucose 6-phosphate dehydrogenase from sheep erythrocytes and inhibitory effects of some antibiotics on enzyme activity. J Enzyme Inhib Med Chem 2002;17:271–7
   PubMed Web of Science ®Google Scholar
• Ciftci M, Beydemir S, Ekinci D. Effects of some drugs on enzymatic activity of glucose 6-phosphate dehydrogenase from chicken erythrocytes in vitro. Asian J Chem 2008;20:2189–96
   Web of Science ®Google Scholar
• Ekinci D, Beydemir S, Alim Z. Some drugs inhibit in vitro hydratase and esterase activities of human carbonic anhydrase-I and II. Pharmacol Rep 2007;59:580–7
   PubMed Web of Science ®Google Scholar
• Senturk M, Ekinci D, Alici HA, Beydemir S. Paraoxonase-1, an organophosphate detoxifier and cardioprotective enzyme, is inhibited by anesthetics: an in vitro and in vivo insight. Pest Biochem Physiol 2011;101:206–11
   Web of Science ®Google Scholar
• Alici HA, Ekinci D, Beydemir S. Intravenous anesthetics inhibit human paraoxonase-1 (PON1) activity in vitro and in vivo. Clin Bioch 2008;41:1384–90
   PubMed Web of Science ®Google Scholar
• Ekinci D, Beydemir S. Evaluation of the impacts of antibiotic drugs on PON 1; a major bioscavenger against cardiovascular diseases. Eur J Pharmacol 2009;617:84–9
   PubMed Web of Science ®Google Scholar
• Dilek EB, Kufrevioglu OI, Beydemir S. Impacts of some antibiotics on human serum paraoxonase 1 activity. J Enzyme Inhib Med Chem 2013;28:758–64
   PubMed Web of Science ®Google Scholar
• Alim Z, Beydemir S. Effects of some anti-neoplastic drugs on sheep liver sorbitol dehydrogenase. Arch Physiol Biochem 2012;118:244–52
   PubMed Web of Science ®Google Scholar
• Soyut H. In vitro inhibitory effects of ofloxacin hydrochloride, ampicillin sodium, cefotaxime sodium, and ceftizoxime sodium on purified paraoxonase-1 (hPON1) from human serum. Scholarly J Phys Appl Chem 2013;1:10–16
   Google Scholar
• Soyut H. In vitro inhibitory effects of clarithromycin, cefepime hydrochloride, acycloviron, and cefazolin sodium on purified paraoxonase-1 from human serum. Int J Appl Chem 2013;1:9–20
   Google Scholar
• Turkes C, Soyut H, Beydemir S. Inhibition effects of gemcitabine hydrochloride, acyclovir, and 5-fluorouracil on human serum paraoxonase-1 (hPON1): in vitro. Open J Biochem 2013;1:10–15
   Google Scholar
• Turkes C, Soyut H, Beydemir S. Effect of calcium channel blockers on paraoxonase-1 (PON1) activity and oxidative stress. Pharmacol Rep 2014;66:74–8
   PubMed Web of Science ®Google Scholar
• Renault F, Chabriere E, Andrieu JP, et al. Tandem purification of two HDL-associated partner proteins in human plasma, paraoxonase (PON1) and phosphate binding protein (HPBP) using hydroxyapatite chromatograpy. J Chromatogr B 2006;836:15–21
   PubMed Web of Science ®Google Scholar
• Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995;115:243–53
   PubMed Web of Science ®Google Scholar
• Lineweaver H, Burk D. The determination of enzyme dissocation constants. J Am Chem Soc 1934;56:658–66
   Web of Science ®Google Scholar
• Gaidukov L, Tawfik DS. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 2005;44:11843–54
   PubMed Web of Science ®Google Scholar
• Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscl Throm Vas Biol 2001;21:473–80
   PubMed Web of Science ®Google Scholar
• La Du BN, Aviram M, Billecke S, et al. On the physiological role(s) of the paraoxonases. Chem Biol Interact 1999;119:379–88
   PubMed Web of Science ®Google Scholar
• Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004;37:1304–16
   PubMed Web of Science ®Google Scholar
• Rozenberg O, Shih SD, Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 2005;181:9–18
   PubMed Web of Science ®Google Scholar
• Tomas M, Senti M, Garcia-Faria F, et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscl Throm Vas Biol 2000;20:2113–9
   PubMed Web of Science ®Google Scholar
• Mackness B, Durrington PN, Boulton AJM, Hine D. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur Clin Invest 2002;32:259–64
   PubMed Web of Science ®Google Scholar
• Akcay MN, Polat MF, Yilmaz I, Akcay G. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterol 2003;50:225–7
   Google Scholar
• Akcay MN, Yilmaz I, Polat MF, Akcay G. Serum paraoxonase levels in gastric cancer. Hepatogastroenterol 2003;50:273–5
   Google Scholar
• Ferretti G, Bacchetti T, Moroni C, et al. Paraoxonase activity in high density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab 2005;90:1728–33
   PubMed Web of Science ®Google Scholar
• Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007;370:1829–39
   PubMed Web of Science ®Google Scholar
• Kumar A. Effects of simvastatin on paraoxonase 1 (PON1) activity and oxidative stress. Asian Pac J Trop Med 2010;3:310–14
   Web of Science ®Google Scholar
• Nagila A, Permpongpaiboon T, Tantrarongroj S, et al. Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacol Rep 2009;61:892–8
   PubMed Web of Science ®Google Scholar
• Malin R, Laaksonen R, Knuuti J, et al. Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics 2001;11:625–33
   PubMedGoogle Scholar
• Leviev I, James R. Simvastatin increases plasma levels of the antioxidant enzyme paraoxonase by PON1 gene activation. Atheroslerosis 2000;151:41
   Google Scholar
• Blatter-Garin MC, Kalix B, De PS. Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1. Diabetologia 2003;46:593–4
   PubMed Web of Science ®Google Scholar
• Saisho Y, Komiya N, Hirose H. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan. Diabetes Res Clin Pract 2006;74:201–3
   PubMed Web of Science ®Google Scholar
• Spirou A, Rizos E, Liberopoulos EN. Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: a pilot study. J Cardiovasc Pharmacol Ther 2006;11:256–61
   PubMed Web of Science ®Google Scholar
• Senturk M, Alici HA, Beydemir S, Kufrevioglu OI. In vitro and in vivo effects of some benzodiazepine drugs on human and rabbit erythrocyte carbonic anhydrase enzymes. J Enzyme Inhib Med Chem 2012;27:680–4
   PubMed Web of Science ®Google Scholar
• Balaydin H, Soyut H, Ekinci D, et al. Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols including natural products. J Enzyme Inhib Med Chem 2012;27:43–50
   PubMed Web of Science ®Google Scholar
• Gulcin I, Beydemir S, Coban TA, Ekinci D. The inhibitory effect of dantrolene sodium and propofol on 6-phosphogluconate dehydrogenase from rat erythrocyte. Fresenius Environ Bull 2008;17:1283–7
   Web of Science ®Google Scholar
• Gulcin I, Beydemir S, Coban TA, Ekinci D. The inhibitory effect of ethanol on carbonic anhydrase isoenzymes: an in vivo and in vitro study. J Enzyme Inhib Med Chem 2008;23:266–70
   PubMed Web of Science ®Google Scholar
• Kaya ED, Soyut H, Beydemir S. Carbonic anhydrase activity from the gilthead sea bream (Sparus aurata) liver: the toxicological effects of heavy metals. Environ Toxicol Pharmacol 2013;36:514–21
   PubMed Web of Science ®Google Scholar
• Ekinci D, Beydemir S. Purification of PON1 from human serum and assessment of enzyme kinetics against metal toxicity. Biol Trace Elem Res 2010;135:112–20
   PubMed Web of Science ®Google Scholar
• Rodrigo L, Gil F, Herdanez AF, et al. Identification of paraoxonase 3 in rat liver microsomes: purification and biochemical properties. Biochem J 2003;376:261–8
   PubMed Web of Science ®Google Scholar
• Harel M, Aharoni AI, Gaidukov L, et al. Structure and evolution of the serum paraoxonase family of detoxifying and antiatherosclerotic enymes. Nat Struct Mol Biol 2004;11:412–19
   PubMed Web of Science ®Google Scholar